In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharma/Payor Deals An Important Step In The Shift To Value-Based R&D

Executive Summary

Three major drug makers inked broad alliances with the research departments of major US payors in 2011. The alliances signal that even as pharma drug makers reorients its R&D engines to be more flexible and externally focused in the hopes of shedding risk and cost, such moves are not enough.


Related Content

Big Data Transforming The Role Of Pharma, IBM Analytics Partner Says
Payers’ Use Of Real-World Evidence For Drug Coverage On The Rise – IMS Health
Creating Value In Pharma-Health Plan Collaborations
Germany’s Pricing Revolution: Why The World Should Be Watching
A Call For Action: Pharma Strategies For Development Of Payor Evidence Programs
AZ, IMS To Build Disparate Data Sets Into Broader Outcomes Consensus
Biopharma In 2011: A Year Of Transition
Clinical, Not Real-World, Data is Still The Key To On- And Off-Label Reimbursement (Part 2)
AstraZeneca Rebuilds R&D Amid Growing Near-Term Pressures
Building A Biopharma Product's Reimbursement Into Deals


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts